EffCaMgCit

Phase 3Small molecule

UUniversity of Texas Southwestern Medical Center

EffCaMgCit is one of 70 small molecule programs targeting Complication. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney DiseaseActive, not recruiting

OsteoporosisWithdrawn

Chronic Kidney DiseasePhase 2/Phase 3

Active, not recruiting

OsteoporosisPhase 3

Withdrawn

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

EffCaMgCit

UUniversity of Texas Southwestern Medical Center

Phase 3

1 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Vemlidy

Gilead

Preclinical

1 4

Lorelco

Sanofi

Preclinical

1 5

Activase

Roche

Preclinical

—6

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Sodium Valproate

AstraZeneca

Preclinical

4 8

Tradjenta

Boehringer Ingelheim

Preclinical

1 9

Nitrostat

VViatris Specialty LLC

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V

Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2/3·NCT03565913·269 enrolled

Complication1 trial

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT03812380·62 enrolled

Osteoporosis1 trial

Effervescent Calcium Magnesium Citrate to Prevent Mineral Metabolism and Renal Complications of Chronic Proton Pump Inhibitor Therapy

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT05998863

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for EffCaMgCit. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EffCaMgCit compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EffCaMgCit. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Texas Southwestern Medical Center

EffCaMgCit

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease1 trial

Complication1 trial

Osteoporosis1 trial

References

Drug Info

Quick Facts

Related News